Capula Management’s AstraZeneca AZN Stock Holding History

Capula Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$572K	Buy	+2,900	New	+$559K	﹤0.01%	482
2023 Q2	–	Sell	-19,750	Closed	-$2.74M	–	448
2023 Q1	$2.74M	Buy	19,750 +2,200	+13%	+$296K	0.03%	293
2022 Q4	$2.38M	Buy	+17,550	New	+$2.2M	0.03%	328

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Capula Management's AZN Position: Q1 2026 in Review

Capula Management opened a new position in AstraZeneca (AZN) in Q1 2026: 162 shares worth $31.9K. The stake represents ﹤0.01% of the portfolio and ranks #1024 among its holdings.

1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Capula Management held 162 shares of AstraZeneca worth $31.9K as of Q1 2026.
AstraZeneca was a new Capula Management position in Q1 2026.
AstraZeneca made up ﹤0.01% of Capula Management's portfolio in Q1 2026, its #1024 holding.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Capula Management's 13F filing for Q1 2026, filed 14 May 2026.